Personality Pharmacology

Part V · Pharmacology of the Self Draft

Chapter 31

Trait-Targeted Pharmacology

Treatment, Enhancement, and Personalized Optima

Medicine prefers clear borders. A person is ill or well. An intervention is treatment or enhancement. A drug restores normal function or changes a healthy person.

Biology does not respect those borders nearly as cleanly.

Consider social anxiety. At one extreme, fear of social evaluation can prevent relationships, education, work, and ordinary participation in life. Reducing that fear is straightforwardly therapeutic. Continue moving along the same dimension and the person may become conventionally confident. Move farther and they may become unusually socially bold.

At what point did the mechanism stop being treatment and become enhancement?

disablingfearordinarynervousnessconventionallyconfidentunusuallyboldtreatmentenhancementno line hereone dimension of social fear, and onemechanism along all of it
Figure 31.1No border on the line. The same mechanism can be at work from disabling fear to unusual boldness, with no biological event where treatment becomes enhancement.

There is no obvious biological event at the population mean.

The same receptor system, learning process, or threat circuit can be involved on both sides of the diagnostic threshold. The categories remain useful for medicine, regulation, and resource allocation, but they do not describe two fundamentally different kinds of neural change.

This is the opening for trait-targeted pharmacology.

The phrase means something narrower than “designer personality”. It means deliberately choosing a personality-relevant dimension as the target of an intervention rather than treating trait change as an accidental side effect of symptom reduction.

Candidate targets are familiar: social inhibition, emotional intensity, persistence, reward drive, attentional control, threat sensitivity, confidence, openness, cognitive flexibility, attachment, and temporal orientation. Some people already use drugs for precisely these purposes, whether or not medicine acknowledges the practice in those terms.

The important question is not whether a target lies inside or outside a diagnostic category. It is whether the proposed movement is beneficial for this person and whether the costs are acceptable.

This requires a personalized optimum.

Suppose two people are equally inhibited in public speaking. One wants a quiet life and rarely needs to perform. The other has chosen a profession built around teaching. The same trait has different functional costs. There is no reason to push the first person toward a population norm they do not value. There may be a strong reason to help the second gain access to a more confident state.

Person 1, equally inhibitedwants a quiet life; rarely needs to performalready therePerson 2, equally inhibitedchose a profession built around teachingwhere they want to bemore inhibitedmore confidentspeaking in public
Figure 31.2A personal optimum. The same trait has different costs for different lives, so the target is set by goals and context rather than by the population mean.

The optimum is therefore defined relative to goals, context, values, and time horizon.

This does not make every preference medically authoritative. A desired trait change can be poorly informed, dangerous, coerced, or inconsistent with the person’s other goals. Someone may want extreme emotional detachment during a painful breakup and later regret becoming indifferent to people they care about. A person may want relentless productivity while underestimating the value of sleep, relationships, and long-term health.

Desire is data, not proof.

The hardest cases involve authenticity. Pharmacological confidence can feel suspiciously artificial. Confidence earned through repeated success feels legitimate because it has a narrative. Yet both states have neural implementations, and both can feed back into learning. If a drug reduces social fear long enough for a person to discover that they are actually competent, the resulting confidence may eventually become self-sustaining.

Is that less authentic than confidence acquired through an unusually supportive childhood?

The word authentic often hides an unexamined preference for the status quo.

A stronger criterion is reflective endorsement. Does the person understand the change? Does it serve values they recognize as their own? Can they revise or reverse the choice? Do they still endorse it when the acute state is gone?

This last question becomes difficult when the intervention changes values themselves.

A drug that increases affiliation might make a relationship feel more important. A drug that reduces anxiety might make a previously central moral caution feel unnecessary. A stimulant could increase the value assigned to achievement. A psychedelic experience could reorder priorities. The post-intervention person may sincerely endorse a change the pre-intervention person would have rejected.

Which preference has authority?

There is no simple answer because ordinary life already changes values. Falling in love, becoming a parent, surviving illness, joining a community, or undergoing psychotherapy can all alter what a person cares about. Pharmacology differs partly in speed, controllability, and the possibility of direct manipulation.

This creates a requirement for longitudinal consent. When an intervention may alter identity or values, one-time consent at the beginning is not enough. The person should have opportunities to reassess from outside the acute state. Reversibility becomes ethically valuable not merely for safety but for comparison.

Trait-targeted pharmacology also needs stronger outcome measures than “I felt better”. A desirable change should improve the function it was meant to improve without unacceptable collateral effects. Greater confidence that produces reckless financial behavior is not a clean success. Emotional dampening that reduces panic but destroys intimacy has a trade-off that needs to be visible.

This is another reason to prefer state control over permanent maximization. A person may want confidence during social performance, not twenty-four hours a day. They may want analytical focus at work and emotional permeability at home.

The best personality intervention may therefore be one that expands selective access rather than shifting the entire baseline.

This idea collapses the moral difference between treatment and enhancement without collapsing the practical difference. Treatment still deserves priority when suffering is severe. Enhancement still raises distinctive concerns about fairness and competitive pressure. But the ethical analysis should be built from autonomy, risk, coercion, reversibility, agency, and external effects rather than from a mystical line called normality.

Once personality modification is framed this way, the obvious next question is methodological. How would we study it without turning the field into anecdotes, uncontrolled self-experimentation, or pharmaceutical marketing?

The answer is to make the self an experimental system.